Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

12.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
12.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Day 100 Recovery of Absolute Number of Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas.

Biomedicines·2024
Same author

The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.

Leukemia·2024
Same author

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.

Blood cancer journal·2024
Same author

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.

Nature communications·2024
Same author

Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.

Blood advances·2024
Same author

Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy.

Transplantation and cellular therapy·2024

Related Experiment Video

Updated: Oct 27, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.1K

CD5+ diffuse large B-cell lymphoma: a narrative review.

Urshila Durani1,2, Stephen M Ansell1

  • 1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Leukemia & Lymphoma
|July 21, 2021
PubMed
Summary
This summary is machine-generated.

CD5 expression in diffuse large B-cell lymphoma (DLBCL) identifies a distinct subset associated with poorer prognostic factors. Further research is needed to determine optimal treatment strategies for CD5+ DLBCL.

Keywords:
B-cell LymphomaCD5DLBCL

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.0K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

Related Experiment Videos

Last Updated: Oct 27, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.1K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.0K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous lymphoid malignancy.
  • Cell surface cluster of differentiation (CD) 5 expression defines a specific subset of DLBCL.
  • CD5+ DLBCL represents an uncommon but clinically significant entity.

Purpose of the Study:

  • To conduct a narrative review of CD5+ DLBCL.
  • To elucidate the clinical implications and characteristics of CD5+ DLBCL.
  • To explore potential treatment strategies for this DLBCL subset.

Main Methods:

  • Literature review of studies investigating CD5 expression in DLBCL.
  • Analysis of clinical features, prognostic factors, and molecular markers associated with CD5+ DLBCL.
  • Synthesis of current evidence regarding treatment approaches.

Main Results:

  • CD5+ DLBCL accounts for 5-10% of DLBCL cases.
  • Associated with older age, elevated lactate dehydrogenase, B symptoms, extranodal involvement, advanced stage, and higher International Prognostic Index scores.
  • Frequently expresses Bcl-2, MYC, MUM1, and exhibits an activated B-cell (ABC)-like phenotype.
  • CD5 expression appears to have independent prognostic value in DLBCL.

Conclusions:

  • CD5+ DLBCL is a distinct subset with specific clinical and molecular features.
  • Evidence suggests CD5+ DLBCL may have a poorer prognosis.
  • Optimal treatment strategies for CD5+ DLBCL require further investigation, despite recommendations for aggressive regimens.